Online Database of Chemicals from Around the World

异丙基甲基4-(2,1,3-苯并恶二唑-4-基)-2,6-二甲基-1,4-二氢-3,5-吡啶二羧酸酯
[CAS# 131970-21-3]

供应商
APIChem Technology Co., Ltd. 中国 询价快递  
+86 (571) 8678-2096
sales@apichemistry.com
化学品生产商(2009 年起)
Abblis Chemicals LLC 美国 询价快递  
+1 (832) 373-8299
info@abblis.com
化学品生产商
Abcam 美国 询价快递  
us.orders@abcam.com
化学品生产商(1998 年起)
Achemo Scientific Limited 香港 询价快递  
+852 3174-6428
sales@achemo.com
化学品生产商(2010 年起)
Alfa Pyridines 美国 询价快递  
+1 (609) 447-3255
sales@pyridines.info
化学品生产商
Atomole Scientific Co., Ltd. 中国 询价快递  
+86 (27) 8262-4262
sales@atomole.com
化学品生产商(2008 年起)
ChemPacific Corp 美国 询价快递  
+1 (410) 633-5771
sales@chempacific.com
化学品生产商(1995 年起)
Excenen Pharmatech Co., Ltd. 中国 询价快递  
+86 (20) 8565-3352
contact@excenen.com
化学品生产商
Glentham Life Sciences 英国 询价快递  
+44 (2033) 978-798
info@glenthamls.com
化学品供销商(2013 年起)
Santa Cruz Biotechnology, Inc. 美国 询价快递  
+1 (831) 457-3800
scbt@scbt.com
化学品生产商
基本信息
产品名称 异丙基甲基4-(2,1,3-苯并恶二唑-4-基)-2,6-二甲基-1,4-二氢-3,5-吡啶二羧酸酯
英文名 Isopropyl Methyl 4-(2,1,3-Benzoxadiazol-4-Yl)-2,6-Dimethyl-1,4-Dihydro-3,5-Pyridinedicarboxylate
别名 DynaCirc, Prescal, PN-200-110, Clivoten, Esr; (±)-Isradipine; [75695-93-1]
分子结构 CAS 登录号:131970-21-3, 异丙基甲基4-(2,1,3-苯并恶二唑-4-基)-2,6-二甲基-1,4-二氢-3,5-吡啶二羧酸酯
分子式 C19H21N3O5
分子量 371.39
CAS 登录号 131970-21-3
分子行输入简码 SMILES CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC
国际化学标识码 InChI 1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
国际化学标识检索码 InChIKey HMJIYCCIJYRONP-UHFFFAOYSA-N
物理化学性质
密度 1.3±0.1g/cm3 (计算值)
沸点 501.9±60.0°C at 760 mmHg (计算值)
闪点 257.4±32.9°C (计算值)
折射率 1.566 (计算值)
溶解度 Soluble to 50 mM in DMSO and to 20 mM in ethanol
参考文献
(1) Kenneth E. Thummel and Danny D. Shen. Percentage Binding in Plasma, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Bound in Plasma' (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Bound in Plasma' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (22), Heparin (Extensive), Lithium (0), Mycophenolate (MPA: 97.5), Prednisolone (90-95 (<200 ng/ml), ~70(>1 microgm/ml)) and Rapacuronium (50-88) have not been provided here. In all, 280 drugs and their 'Bound in Plasma' values (%) are given in the files here.
(2) Kenneth E. Thummel and Danny D. Shen. Peak Time, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Time' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in hours unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Peak-Time' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (1.3), Enoxaparin (3), Epoetin Alfa (SC: 18, IP:12), Etanercept (SC-SD:72(48-96)), Filgrastim (4-5.8), Heparin (3), Interferon Alfa (IM:3.8,SC:7.3), Interferon Beta (SC:1-8), Lithium (IR:0.5-3, SR:2-6), Mycophenolate (MPA: 1.1-2.2), Prednisolone (1.5+-0.5), Sargramostim (A,SC: 1-3, C,SC:1.5-4) and Streptokinase (0.9+-0.21) have not been provided here. In all, 270 drugs and their 'Peak-Time' values are given in the files here.
(3) Kenneth E. Thummel and Danny D. Shen. Urinary Excretion, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023Urinary Excretion (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had Urinary Excretion values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (Low), Clavulanate (43+-14), Enoxaparin (43), Epoetin alfa (<3), Etanercept (Negligible), Heparin (Negligible), Lithium (95+-15), Mycophenolate (MPA: <1), Prednisolone (26+-9), Rapacuronium (6-22) and Streptokinase (0) have not been provided here. In all, 297 drugs and their Urinary Excretion values (%) are given in the files here.
(4) Kenneth E. Thummel and Danny D. Shen. Volume of Distribution, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Volume of Distribution' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in liters/kg units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Volume of Distribution' values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (0.10+-0.01), Clavulanate (0.21+-0.05), Enoxaparin (0.12+-0.04), Epoetin Alfa (0.033+-0.013 (0.033-0.075)), Etanercept (0.11), Filgrastim (0.15), Heparin (0.058+-0.11) +- 0.1), Infliximab (0.043). Interferon Alfa (0.40+-0.19), Interferon Beta (2.9+-1.8), Lithium (0.66+-0.16), Mycophenolate (MPA: 3.6+-4), Prednisolone (0.42+-0.11), Rapacuronium (0.2-0.5), Sargramostim (A: -, C:2(0.4-18) liters/(m.m)) and Streptokinase (0.08+-0.04) have not been provided here. In all, 284 drugs and their 'Volume of Distribution' values are given in the files here.
(5) Kenneth E. Thummel and Danny D. Shen. Peak Concentration, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Concentrations' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. The units are indicated along with the values. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Structures (and values) for Alteplase (t-PA) (973+-133 ng/ml), Clavulanate (2.8 micro g/ml), Enoxaparin (ACLM: 145+-45 ng/ml, BCLM: 414+-87 ng/ml), Epoetin Alfa (SC: 176+-75 U/l, IP: 375+-123 U/l), Etanercept (IV:2.32 micro-g/ml, SC-SD:1.2 micro-g/ml, SC-MD 3 micro-g/ml), Filgrastim (SC: 4 and 49 ng/ml), Heparin (70+-39 ng/ml), Infliximab (118 micro-g/ml), Interferon Alfa (IV: ~13 ng/ml, IM: 2.0 (1.5-2.6) ng/ml, SC: 1.7 (1.2-2.3) ng/ml), Interferon Beta (IV: 1491+-659 IU/ml, SC: 40+-20 IU/ml), Lithium (IR: 1-2 mM, SR: 0.7-1.2 mM), Mycophenolate (MPA: 8-19 micro-g/ml), Prednisolone (458+-150 ng/ml), Rapacuronium (6-20 micro-g/ml), Sargramostim (A, IV: 5ng/ml, A, SC: 1.5 ng/ml, C, IV: 100 ng/ml, C, SC: 10 ng/ml) and Streptokinase (188+-58 IU/ml) have not been provided here. In all, 304 drugs and their 'Peak-Concentration' values are given in the files here.
市场分析报告
请浏览异丙基甲基4-(2,1,3-苯并恶二唑-4-基)-2,6-二甲基-1,4-二氢-3,5-吡啶二羧酸酯市场分析报告总目录
相关产品
四乙基1,1'-(1,2-乙二基)二(2,5-二甲...  1,1'-(1,6-己烷二基)二(2,5-二甲基-...  2-甲基-2-丙基(1-甲氧基丁基)氨基甲酸酯  2-甲基-2-丙基(1-甲氧基-2-甲基丙基)氨基...  2-甲基-2-丙基(1E)-1-丙烯-1-基氨基甲...  2-甲基-2-丙基(2-甲基-1-丙烯-1-基)氨...  2-甲基-2-丙基(2E)-2-丁烯-1-基氨基甲...  7-{5-O-[二甲基(2-甲基-2-丙基)硅烷基...  1-溴-4-[(1E)-2-硝基-1-丙烯-1-基...  3-(2-萘基)-1-丙胺  (5E)-5-(4-氯苄亚基)-2,2-二甲基环戊...  氯甲氧基(丙基)汞乙酸酯  3-(4-乙氧基-1,2,5-噻二唑-3-基)吡啶  3-(1,2,5-恶二唑-3-基)吡啶  氨基(3-吡啶基)乙腈